Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C (Q28943467)

From Wikidata

Jump to navigation Jump to search

scientific journal article

Language	Label	Description	Also known as
English	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C	scientific journal article

Statements

scholarly article

1 reference

PubMed publication ID

14 March 2017

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C (English)

1 reference

PubMed publication ID

14 March 2017

genome-wide association study

0 references

1 reference

based on heuristic

inferred from title

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

6

object named as

Naoya Sakamoto

1 reference

PubMed publication ID

14 March 2017

Yasuhito Tanaka

1

object named as

Yasuhito Tanaka

1 reference

PubMed publication ID

14 March 2017

20

object named as

Namiki Izumi

1 reference

PubMed publication ID

14 March 2017

13

object named as

Eiji Tanaka

1 reference

PubMed publication ID

14 March 2017

3

object named as

Nao Nishida

1 reference

PubMed publication ID

14 March 2017

10

object named as

Keisuke Hino

1 reference

PubMed publication ID

14 March 2017

author name string

Masayuki Kurosaki

2

1 reference

PubMed publication ID

14 March 2017

Masaya Sugiyama

4

1 reference

PubMed publication ID

14 March 2017

Kentaro Matsuura

5

1 reference

PubMed publication ID

14 March 2017

Nobuyuki Enomoto

7

1 reference

PubMed publication ID

14 March 2017

Hiroshi Yatsuhashi

8

1 reference

PubMed publication ID

14 March 2017

Shuhei Nishiguchi

9

1 reference

PubMed publication ID

14 March 2017

Shuhei Hige

11

1 reference

PubMed publication ID

14 March 2017

Yoshito Itoh

12

1 reference

PubMed publication ID

14 March 2017

Satoshi Mochida

14

1 reference

PubMed publication ID

14 March 2017

Masao Honda

15

1 reference

PubMed publication ID

14 March 2017

Yoichi Hiasa

16

1 reference

PubMed publication ID

14 March 2017

Asako Koike

17

1 reference

PubMed publication ID

14 March 2017

Fuminaka Sugauchi

18

1 reference

PubMed publication ID

14 March 2017

Shuichi Kaneko

19

1 reference

PubMed publication ID

14 March 2017

Katsushi Tokunaga

21

1 reference

PubMed publication ID

14 March 2017

Masashi Mizokami

22

1 reference

PubMed publication ID

14 March 2017

publication date

1 September 2011

1 reference

PubMed publication ID

14 March 2017

Human Molecular Genetics

1 reference

PubMed publication ID

14 March 2017

20

1 reference

PubMed publication ID

14 March 2017

17

1 reference

PubMed publication ID

14 March 2017

3507–3516

1 reference

PubMed publication ID

14 March 2017

describes a project that uses

genome-wide association study

1 reference

based on heuristic

inferred from title

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

New therapeutic approaches to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Thrombocytopenia associated with chronic liver disease

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Hematological and bone marrow effects of ribavirin in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Individual variation in inosine triphosphate accumulation in human erythrocytes

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDR249

21 January 2018

Identifiers

10.1093/HMG/DDR249

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28943467&oldid=2106984957"